Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.
about
A Review of Management of Inflammation in the HIV PopulationSwitch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeVitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals.Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infectionRelationships between renal parameters and serum and urine markers of inflammation in those with and without HIV infectionSuccess of Standard Dose Vitamin D Supplementation in Treated Human Immunodeficiency Virus InfectionAntiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort StudyChanges in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.A randomized, controlled trial of the effect of rilpivirine versus efavirenz on cardiovascular risk in healthy volunteers.Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity.Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.Renal effects of novel antiretroviral drugs.Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth.Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.HIV infection, antiretroviral therapy, and measures of endothelial function, inflammation, metabolism, and oxidative stress.A two-week regimen of high-dose integrase inhibitors does not cause nephrotoxicity in mice.Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.A safety evaluation of raltegravir for the treatment of HIV.Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q28078962-A393DA6F-B588-4199-B3EA-E19C81489B0CQ28553066-1D410941-3D68-45EA-9963-170DCA0CFAF0Q34016783-0192DFAF-0B30-46CC-B776-C8F64CCE6108Q34557631-13B11CC5-CF38-4026-BC68-C5BFE6E26E6CQ35230397-E61463A4-F2D9-41BA-9B55-35D30F068EB3Q35717568-EC86F1F0-26CB-4975-A247-56A15EB088FEQ35814594-5A6F145F-9C41-4149-89CC-6A800200B243Q35974422-41E6E315-2669-4F3B-95E2-730DA9002DABQ36051584-E2D4DBB9-16D0-4031-9FF7-1E0AB4B847D8Q36051942-F7C35AEA-D38C-4D45-83F5-3161A2DA3C8AQ38723259-7A3DA200-C12A-4EEC-BB38-493306BF99D5Q38837077-532DBD7F-D6B5-45A8-A9B6-3443CE32CD29Q38978858-2EFDF747-2F01-4AED-BCEC-B27E659EE218Q38997526-CB8E5E23-D598-4A24-8069-4E618A9EC603Q40051462-CF104924-29EC-49FB-B985-C3AA52D6F3EBQ40089833-80D81AC4-3036-4C16-853B-1F1E7E5C5014Q41079671-ADAE6AE4-E299-41BA-9460-40FEB1AB159BQ41736369-4C363100-8216-404D-9D38-C053AFE67F20Q47377203-068AC11C-42EF-4C32-88A7-4608C67891A4Q52729705-7903CDF0-CE08-4788-A71A-EBE79218B0E7Q54240869-13F76FEF-94C2-4B64-A1A6-591C7FA9E7BFQ57180790-EC637012-4EE4-46E2-B5A5-DAA4FF8E6D76
P2860
Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Effects of switching from efav ...... randomized, controlled trial.
@ast
Effects of switching from efav ...... randomized, controlled trial.
@en
type
label
Effects of switching from efav ...... randomized, controlled trial.
@ast
Effects of switching from efav ...... randomized, controlled trial.
@en
prefLabel
Effects of switching from efav ...... randomized, controlled trial.
@ast
Effects of switching from efav ...... randomized, controlled trial.
@en
P2093
P2860
P1476
Effects of switching from efav ...... randomized, controlled trial.
@en
P2093
Michael P Dubé
Samir K Gupta
Sharon M Moe
P2860
P304
P356
10.1097/QAI.0B013E3182A97C39
P407
P577
2013-11-01T00:00:00Z